(Q34432445)

2 August 2017

1 reference

title

The levonorgestrel-releasing intrauterine device: a wider role than contraception (English)

1 reference

2 August 2017

1 reference

2

McCowan L

1 reference

2 August 2017

Coleman M

1

1 reference

2 August 2017

Farquhar C

series ordinal

3

1 reference

2 August 2017

publication date

1 May 1997

1 reference

Australian and New Zealand Journal of Obstetrics and Gynaecology

2 August 2017

published in

1 reference

2 August 2017

volume

37

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

195-201

1 reference

Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1479-828X.1997.TB02253.X

Early chorionic activity in women bearing inert IUD, copper IUD and levonorgestrel-releasing IUD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1479-828X.1997.TB02253.X

The mode of action of IUDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1479-828X.1997.TB02253.X

Ovarian function during use of a levonorgestrel-releasing IUD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1479-828X.1997.TB02253.X

Duration of breast-feeding and development of children after insertion of a levonorgestrel-releasing intrauterine contraceptive device.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1479-828X.1997.TB02253.X

Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1479-828X.1997.TB02253.X

Recovery of fertility after use of the levonorgestrel 20 mcg/d or Copper T 380 Ag intrauterine device

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1479-828X.1997.TB02253.X

The risk of pelvic inflammatory disease in women using intrauterine contraceptive devices as compared to non-users

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1479-828X.1997.TB02253.X

Intrauterine devices and pelvic inflammatory disease: an international perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1479-828X.1997.TB02253.X

A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1479-828X.1997.TB02253.X

The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1479-828X.1997.TB02253.X

Compliance considerations with estrogen replacement: withdrawal bleeding and other factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1479-828X.1997.TB02253.X

Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1479-828X.1997.TB02253.X

Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1479-828X.1997.TB02253.X

10.1111/J.1479-828X.1997.TB02253.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference